Skip to main content

Table 2 Guideline adherence to, measured as the probability of, prescription of lipid-lowering medications by year

From: Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register

Year

Primary prevention

Secondary prevention

Crude (%) n = 756,943

Adjusteda (%) n = 238,895

Crude (%) n = 447,423

Adjusteda (%) n = 142,739

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

2007

34.7 (34.3–35.2)

36.2 (34.8–37.5)

70.7 (70.2–71.2)

58.6 (56.8–60.5)

2008

39.0 (38.6–39.4)

40.3 (39.0–41.6)

72.9 (72.4–73.3)

63.0 (61.3–64.7)

2009

42.7 (42.4–43.1)

43.8 (42.4–45.1)

74.7 (74.3–75.1)

66.2 (64.5–67.8)

2010

44.8 (44.5–45.1)

46.3 (44.9–47.6)

74.7 (74.4–75.1)

67.8 (66.2–69.4)

2011

46.8 (46.5–47.1)

46.6 (45.2–48.0)

75.1 (74.8–75.4)

69.1 (67.5–70.7)

2012

47.4 (47.1–47.7)

46.6 (45.2–48.0)

73.6 (73.2–73.9)

67.9 (66.2–69.5)

2013

47.6 (47.3–47.9)

46.6 (45.2–48.0)

71.8 (71.5–72.2)

66.8 (65.1–68.4)

2014

48.3 (48.0–48.6)

46.1 (44.7–47.5)

70.9 (70.5–71.3)

65.9 (64.2–67.5)

  1. aAdjusted for year, county council, type of care, sex, age, HbA1c, eGFR, diabetes duration, diabetes medications, antihypertensives, antiplatelets, blood pressure, microalbuminuria, macroalbuminuria, BMI, physical activity, smoking and cholesterol levels